Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FKBP1A | P62942 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.48 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.46 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9347282 | 1.00 | FKBP1A (0.53) | FKBP1ACYP3A4ALDH1A1KDM4EKMT2A | |
| SCHEMBL5965409 | 0.95 | FKBP1A (0.56) | FKBP1ACYP3A4ALDH1A1KDM4EKMT2A | |
| SCHEMBL15406170 | 0.95 | FKBP1A (0.56) | FKBP1ACYP3A4ALDH1A1KDM4EKMT2A | |
| SCHEMBL1472797 | 0.94 | FKBP1A (0.60) | FKBP1ACYP3A4ALDH1A1KDM4EKMT2A | |
| SCHEMBL1472792 | 0.90 | FKBP1A (0.64) | FKBP1ACYP3A4ALDH1A1KDM4EKMT2A | |
| SCHEMBL1472793 | 0.90 | FKBP1A (0.64) | FKBP1ACYP3A4ALDH1A1KDM4EKMT2A | |
| SCHEMBL13248928 | 0.90 | FKBP1A (0.64) | FKBP1ACYP3A4ALDH1A1KDM4EKMT2A | |
| SCHEMBL5458626 | 0.88 | CYP3A4 (0.54) | FKBP1ACYP3A4ALDH1A1KDM4EKMT2A | |
| SCHEMBL5451605 | 0.88 | CYP3A4 (0.54) | FKBP1ACYP3A4ALDH1A1KDM4EKMT2A | |
| SCHEMBL9352245 | 0.88 | CYP3A4 (0.54) | FKBP1ACYP3A4ALDH1A1KDM4EKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12630566-B2 | KRas G12D inhibitors | Mirati Therapeutics, Inc. (US) | 2026-05-19 | — | — | US | disclosed |
| EP-4216951-B1 | KRAS G12D INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2026-04-01 | — | — | EP | disclosed |
| US-20240309020-A1 | KRAS G12D INHIBITORS | ARRAY BIOPHARMA INC. | 2024-09-19 | — | — | US | disclosed |
| US-11964989-B2 | KRas G12D inhibitors | Mirati Therapeutics, Inc. (US) | 2024-04-23 | — | — | US | disclosed |
| CN-114615981-B | KRAS G12D inhibitors | 米拉蒂治疗股份有限公司 | 2024-04-12 | — | — | CN | disclosed |
| US-20230357277-A1 | KRAS G12D INHIBITORS | ARRAY BIOPHARMA INC. | 2023-11-09 | — | — | US | disclosed |
| US-20230357277-A1 | KRAS G12D INHIBITORS | ARRAY BIOPHARMA INC. | 2023-11-09 | — | — | US | disclosed |
| US-20230279025-A1 | KRAS G12D INHIBITORS | ARRAY BIOPHARMA INC. | 2023-09-07 | — | — | US | disclosed |
| EP-4216951-A1 | KRAS G12D INHIBITORS | Mirati Therapeutics, Inc. (US) | 2023-08-02 | — | — | EP | disclosed |
| US-20230077225-A1 | KRAS G12D INHIBITORS | Mirati Therapeutics, Inc. | 2023-03-09 | — | — | US | disclosed |
| US-11453683-B1 | KRas G12D inhibitors | Mirati Therapeutics, Inc. (US) | 2022-09-27 | — | — | US | disclosed |
| EP-4021444-A1 | KRAS G12D INHIBITORS | Mirati Therapeutics, Inc. (US) | 2022-07-06 | — | — | EP | disclosed |
| CN-114615981-A | KRAS G12D inhibitors | 米拉蒂治疗股份有限公司 | 2022-06-10 | — | — | CN | disclosed |
| WO-2022066646-A1 | KRAS G12D INHIBITORS | Mirati Therapeutics, Inc. (US) | 2022-03-31 | — | — | WO | disclosed |
| WO-2021041671-A1 | KRAS G12D INHIBITORS | Mirati Therapeutics, Inc. (US) | 2021-03-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230279025-A1 | KRAS G12D INHIBITORS | KRAS, NRAS, HRAS | FKBP1A 2425/4885CYP3A4 4108/4885ALDH1A1 2943/4885 |
| US-20230077225-A1 | KRAS G12D INHIBITORS | KRAS, NRAS, HRAS | FKBP1A 2548/4885CYP3A4 3974/4885ALDH1A1 2681/4885 |
| US-12630566-B2 | KRas G12D inhibitors | KRAS, NRAS, HRAS | FKBP1A 2885/4885CYP3A4 4044/4885ALDH1A1 1816/4885 |
| US-20230357277-A1 | KRAS G12D INHIBITORS | KRAS, NRAS, HRAS | FKBP1A 2548/4885CYP3A4 3974/4885ALDH1A1 2681/4885 |
| US-11964989-B2 | KRas G12D inhibitors | KRAS, NRAS, HRAS | FKBP1A 2484/4885CYP3A4 4280/4885ALDH1A1 1957/4885 |
| US-11453683-B1 | KRas G12D inhibitors | KRAS, NRAS, HRAS | FKBP1A 2444/4885CYP3A4 4362/4885ALDH1A1 2055/4885 |
| US-20240309020-A1 | KRAS G12D INHIBITORS | KRAS, NRAS, HRAS | FKBP1A 2548/4885CYP3A4 3974/4885ALDH1A1 2681/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.